Penumbra Inc (PEN) Position Boosted by Baillie Gifford & Co.
Baillie Gifford & Co. boosted its position in Penumbra Inc (NYSE:PEN) by 35.8% during the 4th quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 906,022 shares of the company’s stock after buying an additional 239,008 shares during the period. Baillie Gifford & Co. owned approximately 2.63% of Penumbra worth $110,715,000 at the end of the most recent quarter.
Several other hedge funds and other institutional investors also recently made changes to their positions in the company. PNC Financial Services Group Inc. raised its holdings in shares of Penumbra by 30.8% during the fourth quarter. PNC Financial Services Group Inc. now owns 437 shares of the company’s stock valued at $53,000 after purchasing an additional 103 shares during the period. Zurcher Kantonalbank Zurich Cantonalbank raised its holdings in shares of Penumbra by 10.0% during the fourth quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 2,028 shares of the company’s stock valued at $248,000 after purchasing an additional 185 shares during the period. Xact Kapitalforvaltning AB raised its holdings in shares of Penumbra by 8.2% during the fourth quarter. Xact Kapitalforvaltning AB now owns 5,258 shares of the company’s stock valued at $643,000 after purchasing an additional 400 shares during the period. Capital Investment Advisory Services LLC acquired a new position in shares of Penumbra during the fourth quarter valued at about $56,000. Finally, Great West Life Assurance Co. Can raised its holdings in shares of Penumbra by 15.8% during the fourth quarter. Great West Life Assurance Co. Can now owns 3,739 shares of the company’s stock valued at $440,000 after purchasing an additional 509 shares during the period. Hedge funds and other institutional investors own 81.08% of the company’s stock.
In other news, Director Harpreet Grewal sold 666 shares of the stock in a transaction that occurred on Thursday, January 3rd. The shares were sold at an average price of $121.27, for a total transaction of $80,765.82. Following the completion of the transaction, the director now directly owns 13,247 shares of the company’s stock, valued at approximately $1,606,463.69. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, CEO Adam Elsesser sold 8,000 shares of the stock in a transaction that occurred on Monday, March 11th. The shares were sold at an average price of $139.86, for a total transaction of $1,118,880.00. Following the transaction, the chief executive officer now directly owns 1,115,838 shares of the company’s stock, valued at $156,061,102.68. The disclosure for this sale can be found here. Over the last three months, insiders have sold 14,752 shares of company stock valued at $2,047,291. 10.70% of the stock is currently owned by insiders.
Shares of NYSE:PEN traded down $1.11 during midday trading on Thursday, hitting $147.61. 20,854 shares of the company’s stock were exchanged, compared to its average volume of 407,278. The company has a market cap of $5.13 billion, a PE ratio of 289.42, a PEG ratio of 8.33 and a beta of 0.79. Penumbra Inc has a 12 month low of $110.84 and a 12 month high of $167.35.
Penumbra (NYSE:PEN) last posted its earnings results on Tuesday, February 26th. The company reported $0.13 EPS for the quarter, topping the consensus estimate of $0.12 by $0.01. The company had revenue of $120.80 million during the quarter, compared to the consensus estimate of $114.93 million. Penumbra had a net margin of 1.48% and a return on equity of 4.42%. The firm’s revenue for the quarter was up 25.7% on a year-over-year basis. During the same period in the previous year, the firm posted $0.25 earnings per share. As a group, equities research analysts predict that Penumbra Inc will post 0.83 earnings per share for the current year.
Penumbra Company Profile
Penumbra, Inc designs, develops, manufactures, and markets medical devices in the United States, Europe, Canada, Australia, Japan, and internationally. The company offers neurovascular access systems designed to provide intracranial access for use in a range of neurovascular therapies under the Neuron, Neuron MAX, Select, BENCHMARK, DDC, and PX SLIM brands; aspiration based thrombectomy systems and accessory devices, including revascularization device for mechanical thrombectomy, such as Penumbra System under the ACE and the 3D Revascularization Device brands.
Featured Story: P/E Growth (PEG)
Receive News & Ratings for Penumbra Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Penumbra and related companies with MarketBeat.com's FREE daily email newsletter.